Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs NowPatient

FuturHealth
Graded #219

Higher grade

vs+0.09999999999999432
NowPatient
Graded #222

Lower grade

The verdict

FuturHealth takes it — 65.6/100 to 65.5/100, but only just.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added NowPatient is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFuturHealth +25
60
35
Dose & formulationNowPatient +12
81
93
Clinical oversightNowPatient +19
67
86
Labs & monitoringFuturHealth +7
61
54
FulfillmentNowPatient +8
62
70
Contract termsEven
55
55
FuturHealth · left barNowPatient · right bar

The numbers

MetricFuturHealthNowPatient
WeighScore65.6/10065.5/100
GradeCC
Scorecard rank#219#222
Semaglutide$199/mo (compounded)$1,349/mo (brand Wegovy)
TirzepatideNot disclosed$1,069/mo (brand Mounjaro, promotional rate)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
FuturHealth

Graded #219 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
NowPatient

Graded #222 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard